For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but
without HBeAg loss, switching to peg-interferon may increase the response rate. In the
investigators study, patients were divided into two groups. In Group A, patients continued
entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a
monotherapy for 48 weeks, then followed up 24 weeks.